Clinical trials: Mild-to-moderate Ulcerative Colitis
Acute Ulcerative Colitis
TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
The purpose of this research study was to compare the medication TP05 to the medication Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and tolerability of TP05.
- Trial name
- Precision-UC (NCT01903252)
- Testing
- TP05, Asacol 400 mg
- Where
- Switzerland
- Volunteers
- 817 people
- Sponsor
- Tillotts Pharma AG
Ulcerative Colitis
ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.
This is a multi-center trial in the US and Europe to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis…
- Trial name
- NCT00063830
- Testing
- Alicaforsen
- Where
- United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Inflammatory Bowel Disease, Ulcerative Colitis
Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis
To establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after…
- Trial name
- NCT00408174
- Testing
- Balsalazide disodium
- Where
- 88 sites in United States
- Volunteers
- 400 people
- Sponsor
- Bausch Health Americas, Inc.
Colitis, Ulcerative
Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis
The aim of this study was to investigate the safety and efficacy of SPD476 2.4 g/day given twice daily ([BID] ie 1.2 g/day BID) and SPD476 4.8g/day given QD compared to placebo in subjects with acute, mild to moderate ulcerative…
- Trial name
- NCT00503243
- Testing
- Delayed and extended release mesalazine
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Shire
Colitis, Ulcerative
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M
IBD98-M-2002 is a phase 2a , Randomized, Double blind, Placebo-controlled of IBD98-M Delayed Release capsules in subjects with Mild to Moderately Ulcerative Colitis to investigate the clinical efficacy of IBD98-M delayed release…
- Trial name
- NCT02493712
- Testing
- High dose, Low dose
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Mild to Moderate Ulcerative Colitis
Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)
This is a multi-center study in Ireland and United Kingdom to determine the effects, safety and tolerability of a drug called CyCol™ in improving mild to moderate ulcerative colitis (UC).
- Trial name
- NCT01033305
- Testing
- CyCol™
- Where
- 22 sites in Ireland, United Kingdom
- Volunteers
- 118 people
- Sponsor
- Sigmoid Pharma
Ulcerative Colitis
A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis
- Trial name
- ECO-RESET (NCT03759041)
- Testing
- Vancomycin Pre-Treatment, SER-287
- Where
- 93 sites in United States, Canada
- Volunteers
- 203 people
- Sponsor
- Seres Therapeutics, Inc.
Colitis, Ulcerative
A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis
The purpose of this research study is to: 1) Test the safety and tolerability of 2 different oral doses of SRT2104 in subjects with ulcerative colitis 2) Determine the amount of SRT2104 measured from a single blood sample in…
- Trial name
- NCT01453491
- Testing
- SRT2104
- Where
- 13 sites in United States
- Volunteers
- 17 people
- Sponsor
- Sirtris, a GSK Company
Ulcerative Colitis
Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis
The purpose of this study is to compare the maintenance of mild to moderate ulcerative colitis remission with six months of treatment with 1.5 grams of mesalamine pellets each day versus placebo.
- Trial name
- NCT00744016
- Testing
- Granulated mesalamine
- Where
- United States
- Volunteers
- 305 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis
To assess the safety and tolerability of single subcutaneous (SC) and intravenous (IV) doses of AMG 181 in healthy subjects and of a single SC dose in subjects with mild to moderate ulcerative colitis (UC)
- Trial name
- NCT01164904
- Testing
- Amg 181
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Amgen
Ulcerative Colitis
Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients
This is a Phase IIa (proof of concept), randomized, double blind, placebo-controlled, multicentre clinical trial to evaluate the safety and efficacy of daily PBF-677 oral treatment during 28 days in Ulcerative colitis (UC)…
- Trial name
- ADENOIBD (NCT03773952)
- Testing
- PBF-677
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Palobiofarma SL
Ulcerative Colitis
A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis
The purpose of the study is to obtain a first clinical assessment of the safety of dersalazine sodium in ulcerative colitis patients with mild to moderate disease.
- Trial name
- NCT00808977
- Testing
- Dersalazine sodium, Mesalazine
- Where
- 22 sites in Belgium, Hungary and 2 more
- Volunteers
- 80 people
- Sponsor
- Palau Pharma S.L.U.
Ulcerative Colitis
A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)
This study was conducted to determine the efficacy and safety of GWP42003 compared with placebo by the percentage of participants achieving remission quantified as a Mayo score of 2 or less (with no sub-score >1) after 10 weeks…
- Trial name
- NCT01562314
- Testing
- GWP42003
- Where
- 8 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- GW Research Ltd
Ulcerative Colitis
ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis
This is a multi-center trial to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis (UC).
- Trial name
- NCT00063414
- Testing
- Alicaforsen
- Where
- United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Ulcerative Colitis
Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
SPH3127-US-01 is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SPH3127 for the treatment of mild-to-moderate ulcerative colitis.
- Trial name
- NCT05019742
- Testing
- SPH3127
- Where
- 16 sites in United States
- Volunteers
- 3 people
- Sponsor
- Shanghai Pharma Biotherapeutics USA Inc.
Proctitis, Proctosigmoiditis
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
The purpose of this study is to establish the efficacy profile of rectally administered budesonide foam, as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in participants who…
- Trial name
- NCT01008423
- Testing
- Budesonide
- Where
- 62 sites in United States
- Volunteers
- 281 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment
The study will evaluate the effectiveness, safety and tolerability of tacrolimus lipid suspension for enema in adult patients with mild to moderately active ulcerative colitis who had an inadequate response or intolerance of at…
- Trial name
- NCT06867042
- Testing
- Tacrolimus Lipid Suspension for enema, Identical Tacrolimus-free Lipid Suspension for Enema
- Volunteers
- 150 people
- Sponsor
- Jina Pharmaceuticals Inc.
Inflammation, Ulcerative Colitis
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
This trial is conducted in Europe. The aim of the trial is to investigate the effect of recombinant factor XIII (rFXIII) administered to subjects with mild to moderate active ulcerative colitis (UC).
- Trial name
- NCT01706159
- Testing
- catridecacog
- Where
- 7 sites in Bulgaria, Croatia and 5 more
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Distal Ulcerative Colitis
QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)
This national, observational and multicentre study aims at establishing a picture of real clinical practices management among patients treated with Pentasa®, according to the current therapeutic strategy in proctitis or distal…
- Trial name
- QUARTZ (NCT02368743)
- Testing
- mesalazine
- Where
- France
- Volunteers
- 117 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects…
- Trial name
- NCT04314375
- Testing
- Low Dose Budesonide, High Dose Budesonide
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bausch Health Americas, Inc.